English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu“Our team of internationally recognized physicians and translational researchers looks forward to sharing practice updates and elucidating the latest GI treatment innovations in order to further enhance our collective knowledge in the field,” notes Howard S. Hochster, MD, FACP, director of the Rutgers Cancer Institute of New Jersey Gastrointestinal Oncology Program and Associate Director for Clinical Research and director of Oncology Research at RWJBarnabas Health.
The full list of presentations at this year’s Gastrointestinal Cancers Symposium is as follows:
|
Oral Presentations |
||
|
Abstract |
Title |
Presentation Date/Time |
|
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. |
January 20, 2023 at 4:30 PM EST |
|
|
Poster Presentations |
||
|
Abstract |
Title |
Presentation Date/Time |
|
|
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922. |
January 20, 2023 at 3:00 PM EST |
|
|
Circulating Tumor DNA-Based Genomic Landscape of KRAS Wild-type Pancreatic Adenocarcinoma |
January 20, 2023 at 3:00 PM EST |
|
HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer—Preliminary efficacy and correlative results. |
January 21, 2023 at 9:30 AM |
|
|
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. |
January 21, 2023 at 9:30 AM |
|
|
|
Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer. |
January 21, 2023 at 9:30 AM |
|
|
Poster Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab
|
January 21, 2023 at 9:30 AM |
|
|
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). |
January 21, 2023 at 9:30 AM |
|
|
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC). |
January 21, 2023 at 9:30 AM |
|
|
Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01). |
January 21, 2023 at 9:30 AM |
The poster presentations will be available on Thursday, January 19, 2023 on the conference website.
About Rutgers Cancer Institute of New Jersey As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
